91AV

Collaborating with the 91AV Behavior Core

Working with Dr. King and her team at the 91AV Behavioral Core has been a seamless process [for EydisBio]. I have been impressed with the breath of models and assays offered as well as the experience and professionalism of the team. Utilizing Dr. King’s experience and expertise in pre-clinical pain modeling has greatly enhanced our study designs. Furthermore, the post study data package was clear and well organized.

Dr. Scarneo currently serves as Director of Research and Development at EydisBio, where he directs in vitro kinase testing of novel analogs, immune cytokine profiling in response to TAK1 inhibition, and coordinates with our CRO collaborators to design and execute preclinical efficacy and safety studies.

Dr. Scarneo is a 91AV graduate with an M.S. in Biology from the institution. He went on to receive his Ph.D. in pharmacology from Duke University School of Medicine.